Capri S, Porta C, Delea TE. Cost-effectiveness of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian national health service perspective. Clin Ther 2017;39(3):567-80. - PAI - Policy Analysis Inc.

Capri S, Porta C, Delea TE. Cost-effectiveness of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian national health service perspective. Clin Ther 2017;39(3):567-80. - PAI - Policy Analysis Inc.